← Back to Screener
Bionano Genomics, Inc. Common Stock (BNGO)
Price$1.31
Favorite Metrics
Price vs S&P 500 (26W)-42.59%
Price vs S&P 500 (4W)2.68%
Market Capitalization$14.31M
All Metrics
Book Value / Share (Quarterly)$4.14
P/TBV (Annual)0.39x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)0.84%
Cash Flow / Share (Quarterly)$-1.52
Price vs S&P 500 (YTD)-19.82%
Gross Margin (TTM)46.25%
Net Profit Margin (TTM)-92.59%
EPS (TTM)$-5.51
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-5.51
Revenue Growth (5Y)27.38%
EPS (Annual)$-4.85
ROI (Annual)-54.81%
Gross Margin (Annual)46.25%
Net Profit Margin (5Y Avg)-396.04%
Cash / Share (Quarterly)$1.79
Revenue Growth QoQ (YoY)-2.60%
ROA (Last FY)-35.87%
Revenue Growth TTM (YoY)-7.37%
EBITD / Share (TTM)$-3.25
ROE (5Y Avg)-138.50%
Operating Margin (TTM)-116.95%
Cash Flow / Share (Annual)$-1.52
P/B Ratio0.32x
P/B Ratio (Quarterly)0.35x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.53x
Net Interest Coverage (TTM)-127.56x
ROA (TTM)-34.38%
EPS Incl Extra (Annual)$-4.85
Current Ratio (Annual)1.98x
Quick Ratio (Quarterly)1.51x
3-Month Avg Trading Volume0.29M
52-Week Price Return-68.15%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.73
P/S Ratio (Annual)0.50x
Asset Turnover (Annual)0.39x
52-Week High$5.50
Operating Margin (5Y Avg)-391.00%
EPS Excl Extra (Annual)$-4.85
CapEx CAGR (5Y)11.41%
Tangible BV CAGR (5Y)3.59%
26-Week Price Return-33.85%
Quick Ratio (Annual)1.59x
13-Week Price Return-16.77%
Total Debt / Equity (Annual)0.08x
Current Ratio (Quarterly)1.98x
Enterprise Value$15.048
Revenue / Share Growth (5Y)45.06%
Asset Turnover (TTM)0.37x
Book Value / Share Growth (5Y)17.49%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.85x
Pretax Margin (Annual)-92.35%
Cash / Share (Annual)$1.79
3-Month Return Std Dev82.64%
Gross Margin (5Y Avg)23.38%
Net Income / Employee (TTM)$-0
ROE (Last FY)-59.42%
Net Interest Coverage (Annual)-10.84x
EPS Basic Excl Extra (Annual)$-4.85
Receivables Turnover (TTM)5.73x
Total Debt / Equity (Quarterly)0.08x
EPS Incl Extra (TTM)$-5.51
Receivables Turnover (Annual)5.73x
ROI (TTM)-52.06%
P/S Ratio (TTM)0.50x
Pretax Margin (5Y Avg)-400.92%
Revenue / Share (Annual)$5.24
Tangible BV / Share (Annual)$3.73
Price vs S&P 500 (52W)-103.24%
Year-to-Date Return-15.69%
5-Day Price Return9.32%
EPS Normalized (Annual)$-4.85
ROA (5Y Avg)-70.55%
Net Profit Margin (Annual)-92.59%
Month-to-Date Return10.26%
Cash Flow / Share (TTM)$-6.78
EBITD / Share (Annual)$-4.05
Operating Margin (Annual)-116.95%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-129.36%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.51
P/TBV (Quarterly)0.39x
P/B Ratio (Annual)0.35x
Inventory Turnover (TTM)1.85x
Pretax Margin (TTM)-92.36%
Book Value / Share (Annual)$4.14
Price vs S&P 500 (13W)-19.64%
Beta1.74x
Revenue / Share (TTM)$2.77
ROE (TTM)-56.22%
52-Week Low$1.06
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Lab Analytical Instruments(22)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
BNGOBionano Genomics, Inc. Common Stock | 0.50x | 27.38% | 46.25% | -116.95% | $1.31 |
AAgilent Technologies Inc. | 4.83x | 5.41% | 52.60% | 20.40% | $120.96 |
WATWaters Corp | 10.18x | 6.00% | 59.28% | 25.36% | $335.61 |
MTDMettler-Toledo International | 6.66x | 5.47% | 59.37% | 26.05% | $1324.66 |
ILMNIllumina Inc | 4.69x | 6.04% | 66.61% | 18.44% | $132.86 |
RVTYRevvity, Inc. | 3.64x | -5.46% | 54.77% | 12.49% | $93.03 |
BIOBio-Rad Laboratories, Inc.Class A | 3.17x | 0.29% | 52.01% | 1.59% | $303.34 |
BIO.BBio-Rad Laboratories, Inc. Class B | 3.17x | 0.29% | 52.01% | 1.59% | $277.00 |
BRKRBruker Corporation | 1.81x | 11.57% | 47.13% | 1.40% | $41.10 |
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | 1.81x | 11.57% | 47.13% | 1.40% | $320.13 |
AVTRAvantor, Inc. | 0.88x | 0.49% | 32.65% | -3.83% | $8.50 |
About
Bionano Genomics develops optical genome mapping systems for detecting structural variations, enabling the discovery of new diagnostics and therapeutic targets in pharmaceutical and clinical research. The company generates revenue from its Saphyr platform, instruments, and consumables, with EMEA as its largest geographic market and operations spanning the Americas, EMEA, and Asia Pacific.